Pyrazoloquinoline derivatives
US8563565B2 · kind B2 · utility
31Cited by
0References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 4, 2012 |
| Grant date | Oct 22, 2013 |
| Priority date | — |
| Expiry date | Oct 4, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has a potential use of a therapeutic agent for cognitive dysfunctions in Alzheimer's disease.wherein R1 is a hydrogen atom; R2 is an aromatic ring group, etc.; R3 is a hydrogen atom, etc; R4 is a hydrogen atom; R5 is an oxepanyl group, etc.; R6 is a hydrogen atom.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.